US medical device regulation - a year of change
This article was originally published in Clinica
Executive Summary
Major legislation aimed at streamlining the FDA's review procedures and making the agency more accountable was enacted in 1997. There were also moves to streamline the FDA's Center for Devices and Radiological Health and product review times were down. Edward Wilson looks at the year's achievements.
You may also be interested in...
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.